| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 18, 2011
Perrigo Company (Nasdaq: PRGO; TASE) and its partner Synthon Pharmaceuticals, Inc. today announced that it has received tentative approval from the...
-
May 16, 2011
Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated...
-
May 10, 2011
Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has agreed to settle all Hatch-Waxman litigation relating to fluticasone lotion brought by...
-
May 3, 2011-- Fiscal third quarter revenue from continuing operations increased $154 million, or 29%, to $692 million
Perrigo Company (Nasdaq: PRGO; TASE) today announced results for its third quarter ended March 26, 2011. Perrigo's Chairman and CEO Joseph C. Papa...
-
May 2, 2011
Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated...
-
Apr 28, 2011
Perrigo Company (Nasdaq: PRGO;TASE) today announced that its Board of Directors declared a quarterly dividend of $0.07 per share, payable on June 14,...
-
Apr 21, 2011
Perrigo Company (Nasdaq: PRGO; TASE) today announced that the United States Court of Appeals for the fourth Circuit has affirmed an earlier decision...
-
Apr 19, 2011
Perrigo Company (Nasdaq: PRGO; TASE) today announced that it will release financial results for its third quarter fiscal 2011 on Tuesday, May 3, 2011...
-
Apr 13, 2011
Perrigo (Nasdaq: PRGO;TASE) today announced that its partner, Teva Pharmaceutical Industries, Ltd. (Nasdaq: TEVA), has received final OTC approval to...
-
Apr 12, 2011
Perrigo (Nasdaq: PRGO; TASE) today announced that the Detroit Office of the Food and Drug Administration (FDA) has concluded its re-inspection of...